Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival

View Full Paper
Ask AI
Bookmark
Share

Authors

KCKuo‐Kai ChinBBBrian BallTHTamanna Haque

Discussion

Loading...

Member takes

Overview

Multi-center analysis shows poor outcomes in relapsed/refractory AML after menin inhibitors, suggesting HMA and venetoclax may improve responses.

Key Points

  • To characterize treatment outcomes for patients with relapsed or refractory AML after menin inhibitor treatment.
  • Multi-center retrospective study of adults with relapsed or refractory AML after menin inhibitor monotherapy.
  • Data collected from 4 U.S. academic centers between January 2020 and March 2025.
  • Utilized ELN 2022 criteria for defining relapsed and refractory AML.
  • Sixty-two patients (74%) did not respond to menin inhibitors, with an overall response rate of 26%.
  • Of those receiving non-investigational therapy, the CR/CRi rate was 19% and overall response rate was 32%.
  • Median overall survival after non-investigational therapy was 4.4 months.

Cite This Study

Chin et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5e4https://doi.org/10.1182/blood-2025-39
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure2025 · 9 citations
  2. 2Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care2026 · 3 citations
  3. 3The promise of menin inhibitors: from approval to triplet regimens2025 · 11 citations
  4. 4Efficacy and Potential Limitation of the Menin Inhibitor Revumenib Outside Clinical Trials: Extramedullary Response with Central Nervous System Escape in a Case of KMT2A-Rearranged Acute Myeloid Leukemia2026
  5. 5Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study2025 · 1 citations